Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746847 · ClinicalTrials.gov registry record
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 20
- Enrollment target
NCT03746847: Completed study, sponsored by University of Pennsylvania.
NCT03746847 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746847 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and after treatment using an imaging scan called Positron Emission Tomography / Computed Tomography (PET/CT). Investigators are doing this research study to find out if DOTATATE can help doctors diagnose people with cardiac (heart) sarcoidosis better as well as serve as a follow-up monitoring tool for a response to therapy.
Primary Outcome
The standardized uptake value (SUV) is a nuclear medicine unit commonly used to distinguish between "normal" and "abnormal" levels of tissue uptake.
Interventions
- DRUG Gallium-68 DOTATATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2022-12-01 |
What the finished NCT03746847 record still lists
NCT03746847 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Gallium-68 DOTATATE is the first listed.
NCT03746847 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03746847 about?
NCT03746847 is a clinical study titled "PET Imaging in Patients With Suspected Cardiac Sarcoidosis". Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and a...
What is the current status of trial NCT03746847?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2018-12-01. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03746847?
The interventions under investigation include: Gallium-68 DOTATATE (DRUG).
Who is sponsoring clinical trial NCT03746847?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI